RFK Jr. Stacks FDA Panel With Peptide Backers as Agency Scientists Object

RFK Jr. filled an FDA advisory panel with proponents of peptide therapies he favors, even as agency scientists flagged safety concerns and opposed expanding access to the trendy molecules. The clash highlights tensions between the health secretary's agenda and FDA career staff.